Regenosine

Don't miss our founder and CEO, Dr. Sid Angle, presenting at the Philadelphia Alliance for Capital and Technologies (PACT) Mid-Atlantic Capital Conference 2024 tomorrow! Attending? Make sure to join us at 10:15 a.m. in Salon L to learn more about Regenosine's first-in-class disease-modifying therapy for osteoarthritis. #MACC2024 #Innovation #Investment #Entrepreneurship

Regenosine is excited to be a Featured Company at the 2024 Mid-Atlantic Capital Conference! If you're attending, don’t miss our Founder & CEO, Dr. Sid Angle, presenting on October 30th at 10:15 a.m. in Salon L. We are eager to share updates on our first-in-class disease-modifying therapy for osteoarthritis and connect with leaders across the healthcare and technology industries. #MACC2024 #Innovation #Investment #Entrepreneurship

Regenosine is excited to announce that we have been awarded an SBIR Commercialization Readiness Pilot (CRP) Program grant. This funding will help propel the next stages of clinical development for our first-in-class, disease-modifying regenerative therapy for OA, which is on track to begin Phase I clinical trials in 2025. Learn more at?https://lnkd.in/er24rVDs. #Regenosine #Adenosine #Osteoarthritis #Arthritis #NIH #SBIRGrant #Biotech #ClinicalTrials?

We are thrilled to announce that Regenosine's Founder and CEO, Dr. Sid Angle, will present at the 14th Annual BioNJ BioPartnering Conference on Tuesday, May 14. As one of the emerging?companies in the?field, we welcome discussions with those looking to invest or partner with a company focused on pioneering treatments for osteoarthritis and improving patient outcomes. Learn more at?https://lnkd.in/eNcD6k6R. We look forward to connecting with you there! #BioNJ #BioPartnering #Biotechnology #Innovation #Regenosine #Osteoarthritis #NewJersey

Regenosine is excited to announce that our Founder and CEO Sid Angle will present our groundbreaking research at the prestigious OARSI - Osteoarthritis Research Society International's 2024 World Congress on Osteoarthritis in Vienna, Austria this week. ?? Abstract #377: Intra-articular Injections Of Liposomal Adenosine For Slowing Progression Of Osteoarthritis In A Preclinical Canine Model This study validates the potential of intra-articular liposomal adenosine injections and their capacity to decelerate the progression of osteoarthritis while enhancing pain relief and joint function. If you're attending, let's connect and exchange insights. For those who cannot join, stay tuned for updates on our presentation and the impact this research carries for both veterinary and human medicine. #OARSI2024 #Regenosine #Vetosine #Pain #DiseaseModification #DiseaseModifyingTherapy #Osteoarthritis #OsteoarthritisResearch #VeterinaryMedicine

Last month, our very own Venkatesan Perumal, Senior Scientist at Regenosine, had the pleasure of attending the prestigious DCAT (Drug, Chemical & Associated Technologies Association) dinner in New York City. This black-tie event was a wonderful culmination to this year’s insightful #DCATWeek2024 meetings. A special thank you to our esteemed CDMO partner, Ascendia Pharma, for extending the invitation and sponsoring a night of elegance, insight, and inspiration. One of the evening's highlights was listening to the legendary NFL Star Tom Brady. His talk reminded us all that with dedication and persistence, even the most underestimated can rise to make an incredible impact — a message that resonates deeply with us in our work. #Regenosine #AscendiaPharma #Innovation #Partnership #Inspiration

We are thrilled to share a recently published opinion piece that explores adenosine's vital role in chondrocyte homeostasis and its potential as a new therapeutic target in the treatment of OA.?Read the full article at?https://lnkd.in/eqJVN4sb. #Osteoarthritis #MedicalResearch #Innovation #Regenosine #Adenosine #AdenosineReceptors #PurineMetabolism?Sid Angle Bruce Cronstein